Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein
The DOI matches its Crossref record; 20 of the 21 references it cites were found in a registry or an index.
Abstract
von Hippel-Lindau (VHL) disease is a hereditary cancer syndrome that is characterized by the development of multiple vascular tumors and is caused by inactivation of the von Hippel-Lindau protein (pVHL). Here we show that pVHL, through its beta-domain, binds directly to hypoxia-inducible factor (HIF), thereby targeting HIF for ubiquitination in an alpha-domain-dependent manner. This is the first function to be ascribed to the pVHL beta-domain. Furthermore, we provide the first direct evidence that pVHL has a function analogous to that of an F-box protein, namely, to recruit substrates to a ubiquitination machine. These results strengthen the link between overaccumulation of HIF and development of VHL disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the presence of oxygen (typically > 5% O2), the HIF-α subunit is hydroxylated by PHDs in an iron and oxygen dependent manner, which leads to HIF-α polyubiquitination by pVHL, targeting HIF-α for proteasomal degradation (Figure 2) [8].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [8]
In the citing paper
“As described in the AdPROM section, VHL acts as the substrate receptor for the Cul2-Rbx1 E3 ligase complex, recruiting HIF1α for its ubiquitination and degradation [88].”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [88]
Citations
Cites
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Huang, L. E., Gu, J., Schau, M., & Bunn, H. F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.7987 · Cited by 2,113
Mitochondrial reactive oxygen species trigger hypoxia-induced transcription
Chandel, N. S., Maltepe, E., Goldwasser, E., Mathieu, C. E., Simon, M. C., & Schumacker, P. T. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.20.11715 · Cited by 1,926 · cited 1×
“Whether hypoxia and desferroxamine utilize the same molecular mechanism(s) to stabilize HIF in vivo remains to be determine”
BackgroundSalceda, S., & Caro, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.36.22642 · Cited by 1,674
Structure of the VHL-ElonginC-ElonginB Complex: Implications for VHL Tumor Suppressor Function
Stebbins, C. E., Kaelin, W. G., & Pavletich, N. P. (1999) · Science · doi:10.1126/science.284.5413.455 · Cited by 860
Self-citationStabilization of wild-type p53 by hypoxia-inducible factor 1α
An, W. G., Kanekal, M., Simon, M. C., Maltepe, E., Blagosklonny, M. V., & Neckers, L. M. (1998) · Nature · doi:10.1038/32925 · Cited by 827
Regulation of the Hypoxia-inducible Transcription Factor 1α by the Ubiquitin-Proteasome Pathway
Kallio, P. J., Wilson, W. J., O'Brien, S., Makino, Y., & Poellinger, L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.10.6519 · Cited by 754
Tumour suppression by the human von Hippel-Lindau gene product
Iliopoulos, O., Kibel, A., Gray, S., & Kaelin, W. G. (1995) · Nature Medicine · doi:10.1038/nm0895-822 · Cited by 703
Self-citationBinding of the von Hippel-Lindau Tumor Suppressor Protein to Elongin B and C
Kibel, A., Iliopoulos, O., DeCaprio, J. A., & Kaelin, W. G. (1995) · Science · doi:10.1126/science.7660130 · Cited by 671 · cited 1×
“pVHL normally exists in cells as a complex with elongin B and elongin C rather than as a monome”
BackgroundSelf-citationKamura, T., Sato, S., Haque, D., Liu, L., Kaelin, W. G., Conaway, R. C., & Conaway, J. W. (1998) · Genes & Development · doi:10.1101/gad.12.24.3872 · Cited by 595 · cited 1×
“pVHL normally exists in cells as a complex with elongin B and elongin C rather than as a monome”
BackgroundSelf-citation
Cited by
Items 101–200 of 1,005
The biology of hypoxia: the role of oxygen sensing in development, normal function, and disease
Giaccia, A. J., Simon, M. C., & Johnson, R. (2004) · Genes & Development · doi:10.1101/gad.1243304 · Cited by 380
“Cell lines derived from tumors that have lost the VHL tumor-suppressor gene display aerobic HIF-1 protein expression (Maxwell et al. 1999; Ohh et al. 2000).”
Singhal, R., & Shah, Y. M. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.rev120.011188 · Cited by 376
Makino, Y., Kanopka, A., Wilson, W. J., Tanaka, H., & Poellinger, L. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200328200 · Cited by 375
Niemeyer, C. M., Kang, M. W., Shin, D. H., Furlan, I., Erlacher, M., Bunin, N. J., Bunda, S., Finklestein, J. Z., Sakamoto, K. M., Gorr, T. A., et al. (2010) · Nature Genetics · doi:10.1038/ng.641 · Cited by 374
Self-citationClifford, S. C. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.10.1029 · Cited by 373
Erythropoietin after a century of research: younger than ever
Jelkmann, W. (2007) · European Journal of Haematology · doi:10.1111/j.1600-0609.2007.00818.x · Cited by 367
“The prolyl hydroxylated HIF-1a combines with the von Hippel-Lindau tumour suppressor protein (pVHL) to form a complex that is polyubiquitinated by an E3 ligase (125, 132, 133) and undergoes immediate proteasomal degradation (134).”
BackgroundThe Origin of Allosteric Functional Modulation: Multiple Pre-existing Pathways
del Sol, A., Tsai, C.-J., Ma, B., & Nussinov, R. (2009) · Structure · doi:10.1016/j.str.2009.06.008 · Cited by 366
“…partner proteins (Knauth et al., 2006); (iii) there are more than two binding sites, as in tumor suppressor protein p53 (Riley et al., 2008); pVHL (Ohh et al., 2000); or regulatory proteins in the ubiquitin ligase E3 complex (Hao et al., 2007); (iv) there are multiple modification sites in the…”
BackgroundHIF hydroxylation and the mammalian oxygen-sensing pathway
Safran, M., & Kaelin, W. G. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318181 · Cited by 365
Self-citationAn, S., & Fu, L. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.09.005 · Cited by 363
HIF hydroxylation and the mammalian oxygen-sensing pathway
Safran, M., & Kaelin, W. G. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18181 · Cited by 363
Self-citationKoh, M. Y., Lemos, R., Liu, X., & Powis, G. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4142 · Cited by 350
Expansion of human SCID-repopulating cells under hypoxic conditions
Danet, G. H., Pan, Y., Luongo, J. L., Bonnet, D. A., & Simon, M. C. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17669 · Cited by 345
Akakura, N., Kobayashi, M., Horiuchi, I., Suzuki, A., Wang, J., Chen, J., Niizeki, H., Ki, K., Hosokawa, M., & Asaka, M. (2001) · PubMed · Cited by 399
HIF-1 regulation: not so easy come, easy go
Koh, M. Y., Spivak-Kroizman, T. R., & Powis, G. (2008) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2008.08.002 · Cited by 339
Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL
Hergovich, A., Lisztwan, J., Barry, R., Ballschmieter, P., & Krek, W. (2003) · Nature Cell Biology · doi:10.1038/ncb899 · Cited by 339
The von Hippel-Lindau Tumor Suppressor Protein and Clear Cell Renal Carcinoma
Kaelin, W. G. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1865 · Cited by 336
Self-citationKaelin, W. G. (2007) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.2.010506.092049 · Cited by 336
Self-citationDirect Interactions between HIF-1α and Mdm2 Modulate p53 Function
Chen, D., Li, M., Luo, J., & Gu, W. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c200694200 · Cited by 334
Mitochondrial reactive oxygen species regulate hypoxic signaling
Hamanaka, R. B., & Chandel, N. S. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.08.005 · Cited by 332
“The mechanism of normoxic HIF-1 turnover was elucidated when it was demonstrated that hypoxia inhibits the interaction of HIF-1α with the von Hippel-Lindau (VHL) tumor suppressor protein and that VHL mediates the oxygen-dependent instability of HIF-1α (Figure 2) [22, 23].”
BackgroundPercy, M. J., Zhao, Q., Flores, A., Harrison, C., Lappin, T. R. J., Maxwell, P. H., McMullin, M. F., & Lee, F. S. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508423103 · Cited by 330
Generating specificity and diversity in the transcriptional response to hypoxia
Lendahl, U., Lee, K. L., Yang, H., & Poellinger, L. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2665 · Cited by 330
Oxygen sensors and angiogenesis
Maxwell, P. H., & Ratcliffe, P. J. (2002) · Seminars in Cell & Developmental Biology · doi:10.1006/scdb.2001.0287 · Cited by 329
VHL and HIF signalling in renal cell carcinogenesis
Baldewijns, M. M., van Vlodrop, I. J., Vermeulen, P. B., Soetekouw, P. M., van Engeland, M., & de Bruïne, A. P. (2010) · The Journal of Pathology · doi:10.1002/path.2689 · Cited by 316
“The von Hippel–Lindau (VHL) tumour suppressor protein (pVHL) binds to hydroxylated HIF-α and to elonginC, which recruits elongin-B, cullin-2, and ring-box 1 (RBX1) of an E3 ubiquitin ligase, targeting HIF-α for ubiquitination and degradation by the 26S proteasome [10].”
BackgroundMottet, D., Dumont, V., Deccache, Y., Demazy, C., Ninane, N., Raes, M., & Michiels, C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300763200 · Cited by 316
Hypoxia-inducible Factor and Its Biomedical Relevance
Huang, L. E., & Bunn, H. F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.r200030200 · Cited by 315
McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Franklin, R. A., Montalto, G., Cervello, M., Libra, M., Candido, S., Malaponte, G., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.659 · Cited by 314
Lahiri, S., Roy, A., Baby, S. M., Hoshi, T., Semenza, G. L., & Prabhakar, N. R. (2006) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2005.07.001 · Cited by 312
Genetic analysis of von Hippel-Lindau disease
Nordstrom-O'Brien, M., van der Luijt, R. B., van Rooijen, E., van den Ouweland, A. M., Majoor-Krakauer, D. F., Lolkema, M. P., van Brussel, A., Voest, E. E., & Giles, R. H. (2010) · Human Mutation · doi:10.1002/humu.21219 · Cited by 311
“1) [Feldman et al., 1999; Ohh et al., 2000; Stebbins et al., 1999].”
BackgroundMechanisms of hypoxia signalling: new implications for nephrology
Schödel, J., & Ratcliffe, P. J. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0182-z · Cited by 309
Wiesener, M. S., Münchenhagen, P., Berger, I., Morgan, N. V., Roigas, J., Schwiertz, A., Jürgensen, J. S., Gruber, G., Maxwell, P. H., Löning, S. A., et al. (2001) · PubMed · Cited by 354
Huang, J., Zhao, Q., Mooney, S. M., & Lee, F. S. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206955200 · Cited by 307
Copper Regulation of Hypoxia-Inducible Factor-1 Activity
Feng, W., Ye, F., Xue, W., Zhou, Z., & Kang, Y. J. (2009) · Molecular Pharmacology · doi:10.1124/mol.108.051516 · Cited by 302
“The hydroxylated HIF-1 is recognized by a von Hippel-Lindau protein, which is a constitute of an ubiquitin ligase complex, targeting HIF-1 subunit for degradation by proteasome in cytosol (Maxwell et al., 1999; Ohh et al., 2000; Tanimoto et al., 2000; Masson et al., 2001).”
BackgroundJiang, H., Guo, R., & Powell-Coffman, J. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141234698 · Cited by 302
Elson, D. A., Thurston, G., Huang, L. E., Ginzinger, D. G., McDonald, D. M., Johnson, R. S., & Arbeit, J. M. (2001) · Genes & Development · doi:10.1101/gad.914801 · Cited by 299
“…supported by the demonstration that the von Hippel–Lindau gene product, which targets HIF-1 itself for ubiquitination (Cockman et al. 2000; Ohh et al. 2000; Ivan et al. 2001; Jaakkola et al. 2001), regulates VEGF mRNA expression by upregulating these 3 -UTR-binding proteins (Levy et al.…”
BackgroundReactive oxygen species in the control of hypoxia-inducible factor-mediated gene expression
Kietzmann, T., & Görlach, A. (2005) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2005.03.010 · Cited by 295
Oxygen sensing and hypoxia signalling pathways in animals: The implications of physiology for cancer
Ratcliffe, P. J. (2013) · The Journal of Physiology · doi:10.1113/jphysiol.2013.251470 · Cited by 294
“An important insight into the upstream processes regulating HIF was gained through the recognition that the von Hippel-Lindau tumour suppressor (pVHL) was essential for proteolytic regulation of HIF-α, functioning as a ubiquitin ligase, targeting each of two internal HIF-α domains to mediate oxygen-dependent instabili…”
BackgroundmiR‐210: More than a silent player in hypoxia
Devlin, C., Greco, S., Martelli, F., & Ivan, M. (2011) · IUBMB Life · doi:10.1002/iub.427 · Cited by 289
“Therefore, the net impact of miR-210 on cell proliferation seems to be context dependent. miR-210’s ROLE IN CEREBROVASCULAR AND CARDIOVASCULAR DISEASES The significance of HIF regulation of miR-210 is not limited to cancer, as hypoxia is a central component of other clinical conditions, which have major impacts on mor…”
BackgroundInfluentialSelf-citationJensen, R. L. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9827-2 · Cited by 287
Maynard, M. A., Qi, H., Chung, J., Lee, E. H. L., Kondo, Y., Hara, S., Conaway, R. C., Conaway, J. W., & Ohh, M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m208681200 · Cited by 283
Self-citationHypoxia induced EMT: A review on the mechanism of tumor progression and metastasis in OSCC
Joseph, J. P., Harishankar, M. K., Pillai, A. A., & Devi, A. (2018) · Oral Oncology · doi:10.1016/j.oraloncology.2018.03.004 · Cited by 282
Ubiquitin Ligases and the Immune Response
Liu, Y.-C. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104813 · Cited by 282
Angiogenesis in Endocrine Tumors
Turner, H. E., Harris, A. L., Melmed, S., & Wass, J. A. H. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0008 · Cited by 275
“The VHL protein acts as an E3 ubiquitin ligase specific for HIF -subunits, and this leads directly to oxygen-dependent ubiquination and degradation of HIF in the proteasome (319).”
BackgroundChapter 4: Protein Interactions and Disease
Gonzalez, M. W., & Kann, M. G. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002819 · Cited by 272
Regulation of Angiogenesis by Hypoxia and Hypoxia‐Inducible Factors
Hickey, M. M., & Simon, M. C. (2006) · Current Topics in Developmental Biology · doi:10.1016/s0070-2153(06)76007-0 · Cited by 271
(2001) · PubMed · Cited by 270
Turner, K., Moore, J. W., Jones, A., Taylor, C., Cuthbert-Heavens, D., Cheng, H., Leek, R., Gatter, K. C., Maxwell, P. H., Ratcliffe, P. J., et al. (2002) · PubMed · Cited by 303
Hypoxic but not anoxic stabilization of HIF-1α requires mitochondrial reactive oxygen species
Schroedl, C., McClintock, D. S., Budinger, G. R. S., & Chandel, N. S. (2002) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00014.2002 · Cited by 266
“This binding results in the subsequent degradation of HIF-1 protein through the ubiquitin-proteasome pathway (24, 26).”
BackgroundMylonis, I., Chachami, G., Samiotaki, M., Panayotou, G., Paraskeva, E., Kalousi, A., Georgatsou, E., Bonanou, S., & Simos, G. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605058200 · Cited by 266
The human side of hypoxia‐inducible factor
Smith, T. G., Robbins, P. A., & Ratcliffe, P. J. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07029.x · Cited by 266
“Subsequent research showed that VHL binds to the HIF-a subunit and targets it for ubiquitin-mediated proteasomal degradation by acting as the recognition component of a multiprotein ubiquitin ligase complex (Maxwell et al, 1999; Cockman et al, 2000; Ohh et al, 2000).”
BackgroundRole of Prolyl Hydroxylation in Oncogenically Stabilized Hypoxia-inducible Factor-1α
Chan, D. A., Sutphin, P. D., Denko, N. C., & Giaccia, A. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206922200 · Cited by 264
Beyond oxygen: complex regulation and activity of hypoxia inducible factors in pregnancy
Pringle, K. G., Kind, K. L., Sferruzzi-Perri, A. N., Thompson, J. G., & Roberts, C. T. (2010) · Human Reproduction Update · doi:10.1093/humupd/dmp046 · Cited by 259
“…(Maxwell et al., 1999) by acting as the recognition component of an E3 ubiquitin protein ligase complex (Lisztwan et al., 1999; Cockman et al., 2000; Ohh et al., 2000) to mediate polyubiquitination and proteasomal degradation of HIF-1a under normoxic conditions (Salceda and Caro, 1997; Huang et…”
BackgroundMATEO, J., GARCÍA-LECEA, M., CADENAS, S., HERNÁNDEZ, C., & MONCADA, S. (2003) · Biochemical Journal · doi:10.1042/bj20031155 · Cited by 258
Review: Hypoxia-Inducible Factor-1 (HIF-1): A Novel Transcription Factor in Immune Reactions
Hellwig-Bürgel, T., Stiehl, D. P., Wagner, A. E., Metzen, E., & Jelkmann, W. (2005) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2005.25.297 · Cited by 254
Born to bind: the BTB protein–protein interaction domain
Perez‐Torrado, R., Yamada, D., & Defossez, P. (2006) · BioEssays · doi:10.1002/bies.20500 · Cited by 253
“One well-understood role of the ECS complex is to direct the degradation of two transcription factors, HIF-1 and HIF-2 (Hypoxia-inducible factor 1and 2), which are critical mediators of the cellular response to hypoxia.((51)) Under normoxic conditions, HIF-1 and HIF-2 are continually turned over by ECS.”
BackgroundHypoxia, hypoxia-inducible factors (HIF), HIF hydroxylases and oxygen sensing
Webb, J. D., Coleman, M. L., & Pugh, C. W. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0147-7 · Cited by 253
The hypoxia-inducible factors: key transcriptional regulators of hypoxic responses
Bracken, C. P., Whitelaw, M. L., & Peet, D. J. (2003) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s00018-003-2370-y · Cited by 251
Genetic Basis of Cancer of the Kidney
Linehan, W. M., Vasselli, J., Srinivasan, R., Walther, M. M., Merino, M., Choyke, P., Vocke, C., Schmidt, L., Isaacs, J. S., Glenn, G., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-050013 · Cited by 251
Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis
Bunda, S., Burrell, K., Heir, P., Zeng, L., Alamsahebpour, A., Kano, Y., Raught, B., Zhang, Z.-Y., Zadeh, G., & Ohh, M. (2015) · Nature Communications · doi:10.1038/ncomms9859 · Cited by 249
Self-citationVHL Promotes E2 Box-Dependent E-Cadherin Transcription by HIF-Mediated Regulation of SIP1 and Snail
Evans, A. J., Russell, R. C., Roche, O., Burry, T. N., Fish, J. E., Chow, V. W. K., Kim, W. Y., Saravanan, A., Maynard, M. A., Gervais, M. L., et al. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00892-06 · Cited by 248
Self-citationInhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL−/− tumors
Zimmer, M., Doucette, D., Siddiqui, N., & Iliopoulos, O. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.89.2.2 · Cited by 244
“Under normoxic conditions, pVHL binds to the a-regulatory subunits of HIF leading to their polyubiquitination and proteasomal degradation (5, 12).”
BackgroundHypoxic preconditioning protects against ischemic brain injury
Sharp, F. R., Ran, R., Lu, A., Tang, Y., Strauss, K. I., Glass, T., Ardizzone, T., & Bernaudin, M. (2004) · NeuroRX · doi:10.1602/neurorx.1.1.26 · Cited by 243
Genetic basis of kidney cancer: Role of genomics for the development of disease-based therapeutics
Linehan, W. M. (2012) · Genome Research · doi:10.1101/gr.131110.111 · Cited by 243
“The VHL complex targets the hypoxia-inducible factors, HIF1A and EPAS1 (also known as HIF2A), for ubiquitin-mediated degradation in an oxygen-dependent fashion (Duan et al. 1995; Kibel et al. 1995; Kamura et al. 1999; Maxwell et al. 1999; Ohh et al. 2000; Jaakkola et al. 2001).”
BackgroundHughes, S. J., & Ciulli, A. (2017) · Essays in Biochemistry · doi:10.1042/ebc20170041 · Cited by 240
Tanimoto, K. (2003) · Carcinogenesis · doi:10.1093/carcin/bgg132 · Cited by 239
p53 Stabilization and Transactivation by a von Hippel-Lindau Protein
Roe, J.-S., Kim, H., Lee, S.-M., Kim, S.-T., Cho, E.-J., & Youn, H.-D. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.04.006 · Cited by 237
Mennerich, D., Kubaichuk, K., & Kietzmann, T. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.08.005 · Cited by 235
Bunn, H. F. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011619 · Cited by 234
“As shown in Figure 4, this interaction enables the ubiquitin E3 ligase to dock at this complex, thereby triggering the covalent addition of a number of small ubiquitin molecules (Cockman et al. 2000; Ohh et al. 2000).”
BackgroundKuznetsova, A. V., Meller, J., Schnell, P. O., Nash, J. A., Ignacak, M. L., Sanchez, Y., Conaway, J. W., Conaway, R. C., & Czyzyk-Krzeska, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0436037100 · Cited by 232
Regulation of hypoxia-inducible factor 1 by prolyl and asparaginyl hydroxylases
Hirota, K., & Semenza, G. L. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.08.193 · Cited by 229
Kim, C.-H., Cho, Y.-S., Chun, Y.-S., Park, J.-W., & Kim, M.-S. (2002) · Circulation Research · doi:10.1161/hh0202.104923 · Cited by 228
Hypoxia-Inducible Factors 1α and 2α Regulate Trophoblast Differentiation
Cowden Dahl, K. D., Fryer, B. H., Mack, F. A., Compernolle, V., Maltepe, E., Adelman, D. M., Carmeliet, P., & Simon, M. C. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.23.10479-10491.2005 · Cited by 228
Regulatory mechanisms of hypoxia‐inducible factor 1 activity: Two decades of knowledge
Koyasu, S., Kobayashi, M., Goto, Y., Hiraoka, M., & Harada, H. (2018) · Cancer Science · doi:10.1111/cas.13483 · Cited by 225
Regulation of Wound Healing and Fibrosis by Hypoxia and Hypoxia-Inducible Factor-1
Ruthenborg, R. J., Ban, J.-J., Wazir, A., Takeda, N., & Kim, J.-W. (2014) · Molecules and Cells · doi:10.14348/molcells.2014.0150 · Cited by 223
Novel approaches in the therapy of metastatic renal cell carcinoma
Lam, J. S., Leppert, J. T., Belldegrun, A. S., & Figlin, R. A. (2005) · World Journal of Urology · doi:10.1007/s00345-004-0466-0 · Cited by 223
“The VHL gene product, through its adomain, forms a complex with a number of proteins, including elongin C, elongin B, cullin-2 (Cul-2) and Rbx1 [65,73,89].”
BackgroundInfluentialBracken, C. P., Fedele, A. O., Linke, S., Balrak, W., Lisy, K., Whitelaw, M. L., & Peet, D. J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600288200 · Cited by 222
Proteolysis-Targeting Chimeras: Induced Protein Degradation as a Therapeutic Strategy
Ottis, P., & Crews, C. M. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.6b01068 · Cited by 220
Chan, D. A., Kawahara, T. L. A., Sutphin, P. D., Chang, H. Y., Chi, J.-T., & Giaccia, A. J. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.04.010 · Cited by 220
“Mutation of the von Hippel-Lindau gene (VHL), an upstream negative regulator of HIF, accounts for a subset of tumors with elevated HIF levels (Ohh et al., 2000).”
The cellular basis for diverse responses to oxygen
Chandel, N. S., & Budinger, G. R. S. (2007) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2006.10.048 · Cited by 219
Pluripotent stem cell energy metabolism: an update
Teslaa, T., & Teitell, M. A. (2015) · The EMBO Journal · doi:10.15252/embj.201490446 · Cited by 217
“HIF1a and HIF2a are degraded in ambient air (~21% O2 at sea level) by hydroxylation and ubiquitination from O2-dependent prolyl hydroxylases (PHDs) and the von Hippel-Lindau tumor suppressor protein (pVHL), respectively (Maxwell et al, 1999; Ohh et al, 2000; Jaakkola et al, 2001).”
BackgroundHIF prolyl and asparaginyl hydroxylases in the biological response to intracellular O2 levels
Masson, N., & Ratcliffe, P. J. (2003) · Journal of Cell Science · doi:10.1242/jcs.00655 · Cited by 215
The von Hippel–Lindau protein, HIF hydroxylation, and oxygen sensing
Kaelin, W. G. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.08.165 · Cited by 214
Self-citationThe von Hippel–Lindau tumor suppressor protein
Ivan, M., & Kaelin, W. G. (2001) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(00)00152-0 · Cited by 211
Self-citationSearching for the hereditary causes of renal-cell carcinoma
Pavlovich, C. P., & Schmidt, L. S. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1364 · Cited by 209
Methylation-dependent regulation of HIF-1α stability restricts retinal and tumour angiogenesis
Kim, Y., Nam, H. J., Lee, J., Park, D. Y., Kim, C., Yu, Y. S., Kim, D., Park, S. W., Bhin, J., Hwang, D., et al. (2016) · Nature Communications · doi:10.1038/ncomms10347 · Cited by 208
Involvement of Hypoxia-Inducible Factor 1 in Human Cancer.
SEMENZA, G. L. (2002) · Internal Medicine · doi:10.2169/internalmedicine.41.79 · Cited by 208
The Many Facets of Erythropoietin Physiologic and Metabolic Response
Suresh, S., Rajvanshi, P. K., & Noguchi, C. T. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2019.01534 · Cited by 207
“In rabbits, implantation of gelatin sponges soaked with EPO near the bone defects followed by a single high EPO dose of 4900 IU/kg accelerated bone healing and vascularization in the callus (Omlor et al., 2016).”
BackgroundpVHL suppresses kinase activity of Akt in a proline-hydroxylation–dependent manner
Guo, J., Chakraborty, A. A., Liu, P., Gan, W., Zheng, X., Inuzuka, H., Wang, B., Zhang, J., Zhang, L., Yuan, M., et al. (2016) · Science · doi:10.1126/science.aad5755 · Cited by 207
Self-citationCarbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer.
Olive, P. L., Aquino‐Parsons, C., MacPhail, S. H., Liao, S. Y., Raleigh, J. A., Lerman, M. I., & Stanbridge, E. J. (2001) · PubMed · Cited by 206
The von Hippel–Lindau Tumor Suppressor Gene
Kondo, K., & Kaelin, W. G. (2001) · Experimental Cell Research · doi:10.1006/excr.2000.5139 · Cited by 203
Self-citationTranscription Factor Activities Enhance Markers of Drug Sensitivity in Cancer
Garcia-Alonso, L., Iorio, F., Matchan, A., Fonseca, N., Jaaks, P., Peat, G., Pignatelli, M., Falcone, F., Benes, C. H., Dunham, I., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1679 · Cited by 202
Pugh, C. W., & Ratcliffe, P. J. (2003) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00103-7 · Cited by 201
Protein interactions and disease: computational approaches to uncover the etiology of diseases
Kann, M. G. (2007) · Briefings in Bioinformatics · doi:10.1093/bib/bbm031 · Cited by 201
“VHL protein no longer degrades the HIF leading to the expression of angiogenic growth factors and local proliferation of blood vessels [69, 70].”
Regulation of gene expression by oxygen: NF-κB and HIF-1, two extremes
Michiels, C., Minet, E., Mottet, D., & Raes, M. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)01045-6 · Cited by 201
Jab1 interacts directly with HIF-1α and regulates its stability
Bae, M.-K., Ahn, M.-Y., Jeong, J.-W., Bae, M.-H., Lee, Y. M., Bae, S.-K., Park, J.-W., Kim, K.-R., & Kim, K.-W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c100442200 · Cited by 196
NA, X. I., WU, G., RYAN, C. K., SCHOEN, S. R., di’SANTAGNESE, P. A., & MESSING, E. M. (2003) · Journal of Urology · doi:10.1097/01.ju.0000074870.54671.98 · Cited by 194
Maynard, M. A., Evans, A. J., Hosomi, T., Hara, S., Jewett, M. A. S., & Ohh, M. (2005) · The FASEB Journal · doi:10.1096/fj.05-3788com · Cited by 193
Self-citationHumphrey, J. S., Price, K., Gupta, E., Baxter, A., Bird, J., Sonnichsen, D., & Naglich, J. (2003) · Chemoradiation in Cancer Therapy · doi:10.1007/978-1-59259-325-5_21 · Cited by 193
Regulation of endocytosis via the oxygen-sensing pathway
Wang, Y., Roche, O., Yan, M. S., Finak, G., Evans, A. J., Metcalf, J. L., Hast, B. E., Hanna, S. C., Wondergem, B., Furge, K. A., et al. (2009) · Nature Medicine · doi:10.1038/nm.1922 · Cited by 192
Self-citationZimmer, M., Ebert, B. L., Neil, C., Brenner, K., Papaioannou, I., Melas, A., Tolliday, N., Lamb, J., Pantopoulos, K., Golub, T., et al. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.12.004 · Cited by 191
A Cellular Mechanism to Detect and Alleviate Reductive Stress
Manford, A. G., Rodríguez-Pérez, F., Shih, K. Y., Shi, Z., Berdan, C. A., Choe, M., Titov, D. V., Nomura, D. K., & Rape, M. (2020) · Cell · doi:10.1016/j.cell.2020.08.034 · Cited by 191
“This promptedus toaskwhetherCullin-Ring-E3 ligases (CRLs), a familyofE3s known to control stress and developmental signaling (Bellezza et al., 2018; Donato et al., 2017; Lignitto et al., 2019; Ohh et al., 2000;Wanget al., 1999;Werner et al., 2015), are required formyogenesis in vitro.”
BackgroundInfluential
Metadata
- Authors
- Ohh, M., Park, C. W., Ivan, M., Hoffman, M. A., Kim, T.-Y., Huang, L. E., Pavletich, N., Chau, V., & Kaelin, W. G.
- Affiliations
- Brigham and Women's Hospital (US)
- Memorial Sloan Kettering Cancer Center (US)
- Pennsylvania State University (US)
- Corresponding author
- Kaelin, William G.
- Venue
- Nature Cell Biology
- Published
- 2000-06-09
- Volume
- 2
- Issue
- 7
- Pages
- 423-427
- ISSN
- 1465-7392 (ISSN-L)
- 1476-4679
- OpenAlex
- W2147718842
- Cited by
- 1,577
- References
- 21
- Citations by year
- 2026: 23 · 2025: 36 · 2024: 46 · 2023: 36 · 2022: 49 · 2021: 56 · 2020: 59 · 2019: 45 · 2018: 40 · 2017: 50 · 2016: 52 · 2015: 45 · 2014: 62 · 2013: 66 · 2012: 70
- FWCI
- 33.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Cell Biology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Ear and Head Tumors
- Keywords
- von Hippel-Lindau protein, hypoxia-inducible factor, ubiquitination, F-box protein, protein-protein interaction, alpha-domain, von Hippel-Lindau disease, tumor suppressor, vascular tumors, E3 ubiquitin ligase
- MeSH terms
- Elongin, Cell Extracts, Deferoxamine, DNA-Binding Proteins, HeLa Cells, Humans, Ligases, Mutation, Nuclear Proteins, Oxygen, Protein Binding, Protein Processing, Post-Translational, Proteins, Transcription Factors, Transfection, Tumor Cells, Cultured, Ubiquitins, Protein Structure, Tertiary, Tumor Suppressor Proteins, Ubiquitin-Protein Ligases, Hypoxia-Inducible Factor 1, Von Hippel-Lindau Tumor Suppressor Protein, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.